Cancer Radiation Therapy

According to the American Cancer Society, cancer is the second leading cause of death by disease. More than 1.5 million new cancer cases were are diagnosed in the United States each year.  According to the Radiological Society of North America, about 50 to 60 percent of cancer patients are treated with radiation at some time during their disease.  

Combinations of surgery, chemotherapy and radiation treatments are the standard for modern cancer therapy. Success is often determined by the ability of patients to tolerate the most aggressive regimen.  Unfortunately, the ability to deliver effective radiation therapy is limited by toxic side effects in healthy tissues.  These side effects often case pauses in therapy and limit the amount of radiation that can be delivered to the tumor.  A therapy that could reduce these side effects in healthy tissue would improve patient quality of life, reduce pauses in therapy and open the door to increased tumor kill through higher radiation doses.

AEOL 10150 in Radiation Therapy

Data in preclinical studies to date suggest that AEOL 10150 may protect healthy tissue against radiation injury. In addition, multiple studies have demonstrated that AEOL 10150 does not interfere with tumor response to radiation therapy or chemotherapy.

We intend to file an IND for AEOL 10150 as a treatment for the side effects of radiation therapy for cancer by the end of 2015 and commence human clinical trials as soon as practiable.  The goal of these trials would be to demonstrate significant reduction in toxic side effects in healthy tissue from radiation therapy.